Clover Health director Carladenise Edwards sells $229,687 in stock By Investing.com
Clover Health director Carladenise Edwards sold 67,160 shares of Class A Common Stock for a total of $229,687 on May 18, 2026. This transaction occurred as the stock trades near $3.50, having gained 46% over the past six months, and leaves Ms. Edwards with 285,432 shares directly owned. Despite the sale, InvestingPro analysis suggests Clover Health is currently undervalued, following a mixed Q1 2026 earnings report with revenue beating expectations but EPS falling short.
Clover Health director Carladenise Edwards sells $229,687 in stock
Carladenise Edwards, a director at Clover Health Investments Corp. (NASDAQ:CLOV), sold 67,160 shares of Class A Common Stock for $229,687 on May 18, 2026, with the stock trading near $3.50. This sale follows the company's recent Q1 2026 earnings report, which showed revenue exceeding analyst expectations but an earnings per share miss. Edwards now directly owns 285,432 shares of Clover Health Class A Common Stock.
Director at Clover Health (NASDAQ: CLOV) sells 67K shares at ~$3.42
A director at Clover Health (CLOV), Carladenise Armbrister Edwards, reported selling 67,160 Class A common shares at a weighted average price of approximately $3.42 per share. The individual orders ranged from $3.41 to $3.43. Following this transaction, Edwards directly holds 285,432 shares of Clover Health.
RSU vesting leads Clover Health (CLOV) interim CFO to tax share withholding
Clover Health's interim CFO, Joseph Clay, had 16,942 Class A shares automatically withheld at $3.47 per share on May 16, 2026, to cover tax obligations from RSU vesting. This tax withholding represents 6.25% of his original RSU grant from February 2024, with remaining RSUs vesting quarterly until February 2028, subject to continued service. Following this transaction, Clay directly holds 1,217,584 Class A shares.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
This article details a Form 144 SEC filing by Clover Health Investments, Corp. (CLOV) concerning the proposed sale of 886,341 shares of Class A common stock by Fidelity Investments, acquired through a stock plan option on April 29, 2025. The filing indicates a neutral impact and sentiment, with an aggregate market value of over $3 million for the shares to be sold.
Clover Health CEO Brady Priest sells $345,097 in shares By Investing.com
Brady Patrick Priest, CEO of Clover Care Services, a subsidiary of Clover Health Investments Corp., sold 98,039 shares of Class A Common Stock for $345,097. Following this transaction, Mr. Priest still holds over 2 million shares. Despite analysts predicting profitability this year, InvestingPro analysis suggests CLOV is currently slightly overvalued.
Clover Health CEO Brady Priest sells $345,097 in shares By Investing.com
Brady Patrick Priest, CEO of Clover Care Services (a subsidiary of Clover Health Investments Corp.), sold 98,039 shares of Class A Common Stock for a total of $345,097 on May 13, 2026. This transaction leaves him with 2,040,222 shares. Despite the company appearing slightly overvalued, analysts are predicting profitability for the current year.
[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity
Brady Patrick Priest, CEO of Clover Care Services, a subsidiary of Clover Health Investments, Corp. (CLOV), reported an open-market sale of 98,039 shares of Class A common stock at $3.52 per share on May 13, 2026. After this transaction, Priest directly holds 2,040,222 shares. This Form 4 filing indicates a moderate impact with a negative sentiment due to the insider selling shares.
Clover Health CEO Brady Priest sells $345,097 in shares
Clover Health CEO Brady Priest sold 98,039 shares of Class A Common Stock for $3.52 per share, totaling $345,097. Following this transaction, Priest directly holds over 2 million shares. Despite the sale, analysts predict Clover Health will be profitable this year, and Q1 2026 revenue exceeded expectations although EPS fell short.
[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity
Clover Health Investments CEO Andrew Toy reported a tax-related share withholding on May 8, 2026, where 85,704 shares of Class A common stock were withheld to cover tax obligations on vesting restricted stock units (RSUs). This was a routine, non-open market transaction, common for equity compensation plans. Following this, Toy directly holds 9,923,301 shares, and the remaining RSUs will continue to vest quarterly until August 8, 2026.
Clover Health (NASDAQ: CLOV) turns Q1 2026 profit as Medicare Advantage revenue surges
Clover Health (NASDAQ: CLOV) reported a significant financial turnaround in Q1 2026, achieving a net income of $27.3 million compared to a loss in the prior year. This profitability was primarily fueled by a 62% surge in total revenues to $749.2 million, driven by substantial growth in Medicare Advantage membership and improved star ratings for its PPO plans. The company also demonstrated strengthened liquidity with operating cash flow of $107.9 million, indicating a positive outlook for funding growth initiatives.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III Investors to Secure Counsel Before Important Deadline - CLOV, CLOVW, IPOC
The Rosen Law Firm is reminding investors of Clover Health Investments, Corp. (CLOV, CLOVW, IPOC) that the lead plaintiff deadline in a securities class action lawsuit is April 6, 2021. The lawsuit alleges that Clover Health made false and misleading statements regarding its business, operations, and prospects, specifically concerning a Department of Justice investigation, undisclosed related-party deals, and misleading marketing practices. Investors who purchased Clover securities during the Class Period (October 6, 2020, and February 4, 2021) or pursuant to the December 2020 merger are encouraged to contact the firm for compensation information.
Clover Health (CLOV) sets 2026 virtual meeting, director elections and Say-on-Pay vote
Clover Health Investments, Corp. (CLOV) announced its 2026 annual stockholder meeting will be held virtually on June 10, 2026. Stockholders will vote on the election of three Class II directors, a non-binding "Say-on-Pay" proposal for 2025 executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The Board recommends voting "FOR" all proposals and has outlined its compensation philosophy focusing on pay-for-performance and aligning executive interests with stockholders.
Clover Health (CLOV) CEO RSU vesting triggers share tax withholding
Brady Patrick Priest, CEO of Clover Care Services, underwent a routine tax-withholding transaction where 36,113 Clover Health Investments Class A Common Stock shares were withheld at $2.19 each. This was to cover tax obligations from vested restricted stock units (RSUs). This transaction is a compensation-related tax settlement and not an open-market sale, leaving Priest with 2,138,261 shares.
Clover Health (CLOV) executive stock withheld to cover RSU tax bill
Clover Health Investments executive Brady Patrick Priest had 15,471 shares of Class A Common Stock withheld at $2.04 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This was an automatic tax-withholding event, not an open-market sale, and relates to 6.25% of an RSU grant from October 2024. Following the transaction, Priest directly holds 2,174,374 Class A shares, with remaining RSUs vesting quarterly until October 2028.
Clover Health (CLOV) CLO reports RSU tax-withholding transaction
Clover Health Investments' Chief Legal Officer, Karen Soares, reported a tax-related share withholding for Restricted Stock Units (RSUs). On April 15, 2026, 10,161 shares were withheld at $2.04 per share to cover tax obligations upon the vesting of 6.25% of an RSU award. Soares now directly holds 1,572,422 shares of Clover Health Class A Common Stock.
Clover Health (CLOV) CEO has 60,765 shares withheld for RSU tax on vesting
Clover Health Investments CEO Andrew Toy had 60,765 shares of Class A Common Stock withheld at $2.04 per share on April 15, 2026, to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs). This transaction, a routine tax-related disposition, leaves Toy with 10,009,005 shares directly owned. The withholding relates to 6.25% of an RSU grant from October 2024, with remaining RSUs vesting quarterly until October 2028 contingent on his continued service.
Clover Health (CLOV) interim CFO has RSU tax shares withheld in Form 4
Clover Health's Interim CFO, Joseph Clay, reported a routine tax-withholding event related to restricted stock units (RSUs) on April 15, 2026. A total of 4,158 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover taxes upon the vesting of 6.25% of an RSU grant. Clay now directly holds 1,234,526 shares of Class A Common Stock, with remaining RSUs vesting quarterly through October 15, 2028, subject to his continued service.
Clover Health (CLOV) executive uses 12,712 shares to cover RSU taxes
Clover Health Investments executive Jamie L. Reynoso had 12,712 shares of Class A Common Stock withheld to cover tax obligations related to the vesting of restricted stock units (RSUs). This transaction, valued at $2.04 per share, occurred on April 15, 2026, and is a routine event for equity compensation. Following the withholding, Reynoso directly holds 2,857,210 shares, with the remaining RSUs scheduled to vest quarterly until October 2028.
Clover Health (CLOV) executive covers RSU taxes with share withholding
Clover Health Investments, Corp. executive Conrad Wai had 23,463 shares of Class A Common Stock withheld at $2.04 per share to cover tax obligations from the vesting of restricted stock units (RSUs) on April 15, 2026. This transaction represents 6.25% of an RSU grant from October 2024, with similar quarterly vestings scheduled until October 2028. Following this event, Wai directly holds 1,169,914 shares and indirectly holds 1,610,482 shares through a family trust.
Clover Health (CLOV) finance VP reports 311,169 unvested RSUs in Form 3
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments, Corp. (CLOV), has filed an initial ownership report (Form 3) disclosing beneficial ownership of 311,169 shares of Class A common stock. These shares are part of unvested time-based restricted stock units granted on June 16, 2025, and December 19, 2025, and represent equity-based compensation rather than open-market transactions. The filing clarifies that this is an initial statement of ownership, not a buy or sell transaction.
Clover Health (CLOV) interim CFO discloses 1.24M-share ownership including RSUs
Clover Health Investments (CLOV) interim CFO Joseph Clay Thornton reported a beneficial ownership of 1,238,684 shares of Class A common stock in an amended Form 3. This total includes 912,860 shares from unvested time-based restricted stock unit awards. The filing clarifies his total equity exposure with the company, dating back to RSU grants in 2024 and 2025.
Clover Health (CLOV) interim CFO discloses 1.24M shares, 912k RSUs on Form 3
Clover Health Investments' interim CFO, Joseph Clay, has filed a Form 3 disclosing his initial beneficial ownership in the company. The filing indicates that Clay holds 1,238,684 shares of Class A common stock, which includes 912,860 shares underlying unvested Restricted Stock Unit (RSU) awards granted on February 16, 2024, October 15, 2024, and December 19, 2025. This Form 3 establishes his baseline equity position as an officer of Clover Health.
Clover Health (CLOV) exec uses 6,197 vested shares for taxes
Clover Health Investments CEO of Medicare Advantage, Jamie L. Reynoso, had 6,197 shares of Class A Common Stock withheld on April 3, 2026, to cover tax obligations. This withholding was due to the vesting of 6.25% of restricted stock units granted on January 3, 2023. Following this transaction, Reynoso directly holds 2,869,922 shares of Class A Common Stock, with remaining RSUs vesting in quarterly installments until January 2027.
Clover Health (CLOV) executive receives 191,261 RSUs vesting through 2030
Clover Health Investments' CEO of Clover Care Services, Brady Patrick Priest, was granted 191,261 shares of Class A Common Stock as time-based restricted stock units (RSUs). These RSUs, part of his equity compensation with no cash purchase price, will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments through April 1, 2030, contingent on his continued employment. Following this award, Priest directly holds 2,189,845 shares of Class A Common Stock.
Clover Health (CLOV) awards 382,522 RSUs to Chief Legal Officer
Clover Health Investments (CLOV) has granted its Chief Legal Officer, Karen Soares, 382,522 Restricted Stock Units (RSUs) of Class A common stock. These RSUs were awarded at no cash cost, increasing her direct ownership to 1,582,583 shares. The vesting schedule dictates that 25% will vest on April 1, 2027, with the remainder vesting in quarterly installments until April 1, 2030, contingent on her continued employment.
Clover Health (CLOV) executive granted 267,766 RSUs and reports large share holdings
Clover Health executive Wai Conrad (CEO of Counterpart Health) was granted 267,766 Restricted Stock Units (RSUs) of Class A common stock, valued at $0.00 per share, indicating a compensation grant. These RSUs will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments until April 1, 2030, conditional on his continued service. Following this transaction, Mr. Conrad directly holds 1,193,377 shares, and a family trust holds an additional 1,610,482 shares indirectly.
Clover Health (CLOV) grants 159,384 RSU-based shares to Medicare Advantage CEO
Clover Health has granted Jamie L. Reynoso, CEO of Medicare Advantage, 159,384 shares of Class A common stock in the form of time-based restricted stock units (RSUs) as equity compensation. These RSUs were awarded at no cash cost per share and will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments until April 1, 2030, subject to continued service. Following this award, Reynoso's direct holdings in Class A common stock total 2,876,119 shares.
Clover Health Announces CFO Transition and Reaffirms 2026 Outlook
Clover Health announced a planned CFO transition, with Peter Kuipers stepping down and interim roles assigned to Clay Thornton and Joseph Oldakowski. The company reaffirmed its full-year 2026 financial guidance, emphasizing confidence in its strategy and financial trajectory despite the leadership change. Spark's AI Analyst rates CLOV stock as Neutral due to mixed financial quality and technical pressures, acknowledging the positive aspects of membership growth and profitability ambitions.
Vanguard amends Schedule 13G/A; reports 0 shares in Clover Health (CLOV)
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership in Clover Health Investments Corp (CLOV). This change results from an internal realignment within Vanguard on January 12, 2026, which led certain subsidiaries to report their beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing, signed on March 26, 2026, indicates that Vanguard no longer holds reportable beneficial ownership in Clover Health under this amendment.
Clover Health CEO Reynoso sells $11,141 in shares By Investing.com
Clover Health Investments Corp.'s CEO of Medicare Advantage, Jamie L. Reynoso, sold 5,833 shares of Class A Common Stock for approximately $11,141. The transaction occurred on March 18, 2026, under a pre-arranged trading plan, leaving Reynoso with over 2.7 million shares. This news follows Clover Health's recent Q4 2025 earnings report, which exceeded revenue expectations, and its announcement of becoming the first health insurance payer to operate on a CMS Aligned Network and TEFCA.
Clover Health (CLOV) Medicare Advantage CEO sells 5,833 shares in planned trade
Clover Health Investments' CEO of Medicare Advantage, Jamie L. Reynoso, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. This sale was executed on March 18, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. Following this transaction, Reynoso directly holds 2,716,735 Class A shares.
RSU vesting triggers tax share withholding at Clover Health (CLOV)
Clover Health Investments' General Counsel, Karen Soares, had 4,528 shares of Class A common stock withheld to cover tax obligations. This occurred on March 15, 2026, when 6.25% of her September 15, 2022, time-based RSU grant vested. After the withholding, Soares directly held 1,200,061 shares of Class A common stock.
Clover Health (CLOV) exec Reynoso has shares withheld to cover RSU tax obligations
Clover Health Investments executive Jamie L. Reynoso had shares automatically withheld on March 14 and 15, 2026, to cover tax obligations arising from vested restricted stock units (RSUs). A total of 15,132 Class A Common shares were withheld at $1.98 per share, which were tax-withholding dispositions rather than open-market sales. Following these transactions, Reynoso directly holds 2,722,568 Class A shares.
Clover Health (CLOV) CEO has shares withheld to cover RSU taxes
Clover Health Investments, Corp.'s CEO of Counterpart Health, Conrad Wai, had 100,195 shares of Class A Common Stock automatically withheld on March 14, 2026, to cover tax obligations. This action was due to the vesting of the final portion of his time-based Restricted Stock Units (RSUs) granted in 2022. Following this, Wai directly holds 925,611 shares, with an additional 1,610,482 shares held indirectly in a family trust.
Clover Health (CLOV) shares Q4 2025 supplemental shareholder Q&A in new 8-K
Clover Health Investments, Corp. (CLOV) has filed an 8-K announcing the publication of a supplemental shareholder Q&A for its fourth-quarter 2025 earnings. This Q&A, dated March 6, 2026, provides written responses to frequently asked questions from shareholders to enhance engagement. The document is furnished as Exhibit 99.1 and is also available on the company's investor relations website.
Clover Health (CLOV) Home Care CEO sells 175,000 shares
Brady Patrick Priest, CEO of Home Care at Clover Health Investments, sold 175,000 shares of Class A Common Stock on March 4, 2026. The shares were sold on the open market at a weighted average price of $2.17 per share, in multiple transactions ranging from $2.16 to $2.18. Following this sale, Priest directly owns 1,998,584 shares of Clover Health's Class A Common Stock.
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
Clover Health has become the first payer to go live on a CMS Aligned Network and TEFCA, facilitating real-time patient access to clinical and claims data in standardized FHIR formats. This achievement, made possible by a collaboration with Kno2 and Clover's subsidiary Counterpart Health, demonstrates that nationwide interoperable data exchange is achievable today. It allows patients to securely request health information and aims to enhance coordinated care within a value-based model.
175,000-share sale reported for Clover (NASDAQ: CLOV) on Form 144
A Form 144 filing for Clover Health Investments, Corp. (NASDAQ: CLOV) reported a proposed sale of 175,000 common shares. The filing, dated March 4, 2026, lists Morgan Stanley Smith Barney LLC as the broker-dealer and details restricted stock lots with various grant dates in 2025 and 2026. This type of filing is a notice of an intended sale rather than a confirmation of a completed transaction.
Clover Health Investments, Corp. (NASDAQ:CLOV) Receives Average Rating of "Hold" from Brokerages
Clover Health Investments, Corp. (NASDAQ:CLOV) has an average "Hold" rating from five brokerages, with a consensus 12-month price target of $3.23. Despite positive guidance for FY-2026 revenue ($2.8B–$2.9B) and projected GAAP profitability, Q4 EPS missed estimates, and the company remains unprofitable. Institutional investors hold 19.77% of the stock.
Medicare insurer Clover Health chases first full-year profit in 2026
Clover Health reported its full-year 2025 results, showing $1.924 billion in total revenues and Medicare Advantage membership of 113,803. The company also provided 2026 guidance, projecting its first full year of GAAP net income profitability between $0 million and $20 million on total revenues of $2.81 billion to $2.92 billion. Management attributed the expected profitability to improving cohort economics, Clover Assistant-driven care, and membership scaling, despite a GAAP net loss of $85.5 million in 2025.
CLOVER HEALTH INVESTMENTS, CORP. /DE SEC 10-K Report
Clover Health Investments, Corp. has released its annual Form 10-K report, detailing financial performance, business operations, and strategic initiatives. The company reported a significant increase in total revenues but also higher net losses and loss per share. Clover Health continues to focus on its Clover Assistant platform, geographical expansion, and new product launches like Counterpart Health, while navigating challenges in profitability, operational and regulatory risks, and market competition.
Clover Health (CLOV) targets 2026 GAAP profitability after 40% revenue growth
Clover Health reported strong 40% revenue growth in 2025, reaching $1.9 billion, and increased Medicare Advantage membership by 38% to 113,803. Despite a GAAP net loss of $86 million in 2025, the company achieved non-GAAP profitability with $22 million in Adjusted EBITDA and $20 million in Adjusted Net Income. Clover Health projects its first full year of GAAP net income profitability in 2026, with revenue guidance between $2.81 billion and $2.92 billion and Adjusted EBITDA of $50-$70 million.
Clover Health Investments, Corp. Class A Common Stock CLOV ) Stock Price Today & Analysis
This article provides a stock analysis for Clover Health Investments, Corp. (CLOV), detailing its current stock price, fundamental financials, and key valuation metrics like market cap, P/S ratio, and EPS. It also serves as a guide for potential investors on how to buy CLOV stock through the Gotrade app, explains the minimum investment, discusses dividend policy, and clarifies trading safety and market hours.
Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026, followed by a webcast at 5:00 p.m. ET. The company, which focuses on providing healthcare to Medicare recipients through its software platform Clover Assistant, will discuss its financial performance and business updates. Investors can register for the webcast through the Investor Relations section of Clover Health's website.
Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026. Management will host a webcast at 5:00 p.m. ET to discuss the results and business updates. The company is focused on providing healthcare access to Medicare recipients, leveraging its Clover Assistant software platform to improve clinical decision-making and health outcomes.
Clover Health CEO Reynoso sells $11860 in shares By Investing.com
Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 4,597 shares for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite the company not being profitable in the last year, InvestingPro projects profitability in the current year, and analysts view the stock as slightly undervalued with price targets between $3.00 and $3.70. Clover Health also reported a significant increase in Medicare Advantage membership and aims for its first full-year GAAP Net Income profitability in 2026, though it missed Q3 2025 EPS estimates while exceeding revenue expectations.
Clover Health CEO Reynoso sells $11860 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 4,597 shares of Class A Common Stock for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite not being profitable in the past year, InvestingPro analysis anticipates Clover Health will achieve profitability this year, with a projected GAAP Net Income profitability in 2026. The company also reported a 53% year-over-year increase in Medicare Advantage membership and its stock is considered slightly undervalued by InvestingPro.
Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November
U.S. stocks traded lower on Wednesday, with the Nasdaq falling significantly, despite energy shares gaining and U.S. retail sales increasing by 0.6% in November. Several companies saw substantial stock movements: High Roller Technologies surged 289% following a new partnership, Clover Health Investments rose 10% on membership growth, and Inspire Veterinary Partners gained 78%. Conversely, BriaCell Therapeutics and Plus Therapeutics dropped over 30% after pricing public offerings, while Hub Cyber Security fell 39% following a reverse stock split.
Clover Health Reports 53% Medicare Advantage Membership Growth and Aims for First Full Year GAAP Net Income Profitability in 2026
Clover Health announced a significant 53% year-over-year increase in its Medicare Advantage membership for 2026, reaching approximately 153,000 members. This growth, driven by strategic market approaches and strong retention, positions the company for its first full year of GAAP Net Income profitability in 2026. Clover's PPO plan, which covers over 97% of its members, leads nationally in clinical quality, supported by its Clover Assistant technology to enhance patient outcomes.
